| Date |
Faculty Preceptor |
Assigned Reading |
| Wednesday, September 9 |
Tal Zaks, MD, PhD |
Three-Year Update of a Randomized Phase IIb Study of the Individualized Neoantigen Therapy Intismeran Autogene (mRNA-4157, V940) Plus Pembrolizumab Versus Pembrolizumab in Resected Melanoma
RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer
|
| Friday, September 11 |
Drew Weissman, MD, PhD |
Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease
In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus
|
| Wednesday, September 16 |
Kathy High, MD |
|
| Wednesday, September 30 |
Carl June, MD |
GPC3-specific dnTGFβRII-armoured CAR T cells for hepatocellular carcinoma
CAR T therapy beyond cancer: the evolution of a living drug
|
| Wednesday, October 7 |
Ali Naji, MD, PhD |
Survival of Transplanted Allogeneic Beta Cells with No Immunosuppression
Stem Cell–Derived, Fully Differentiated Islets for Type 1 Diabetes
Transplantation of chemically induced pluripotent stem-cell-derived islets under abdominal anterior rectus sheath in a type 1 diabetes patient
|
| Wednesday, October 14 |
Paul Offit, MD |
Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults
|
| Wednesday, October 21 |
Nicola Mason, BVetMed, PhD, DACVIM, FRCVS |
Immunological responses and clinical outcomes in dogs with osteosarcoma receiving standard therapy and a Listeria vaccine expressing HER2
A Novel Human Her-2/neu ChimericMolecule Expressed by Listeriamonocytogenes Can Elicit Potent HLA-A2 Restricted CD8-positive T cell Responses and Impact the Growth and Spread of Her-2/neu-positive Breast Tumors
Safety evaluation of the canine osteosarcoma vaccine, live Listeria vector
|
| Monday, November 2 |
Jake Brenner, MD, PhD |
Safer non-viral DNA delivery using lipidnanoparticles loaded with endogenousanti-inflammatory lipids
Targeting DNA-LNPs to Endothelial Cells ImprovesExpression Magnitude, Duration, and Specificity
|
| Wednesday, November 4 |
Peter Lebowitz, MD, PhD |
RIPTACs: A Groundbreaking Approach to Drug Discovery
Degrader-antibody conjugates
|
| Wednesday, November 11 |
Christina Coughlin, MD, PhD |
|
